This grant from the National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) aims to combat the ongoing mpox epidemic. With mpox mirroring STIs in presentation and transmission, particularly among men who have sex with men (MSM), the NNPTCs possess critical expertise. This supplemental funding leverages the NNPTCs’ established sexual health proficiency and extensive national network. The grant will integrate mpox vaccination, diagnosis, and treatment into routine sexual health care by developing and delivering comprehensive training and technical assistance. This support empowers healthcare providers and clinical settings to adopt a syndemic approach, enhancing public health efforts against mpox through integrated prevention and care strategies.
Opportunity ID: 346796
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-PS20-20040401SUPP23 |
| Funding Opportunity Title: | The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 93.978 — Sexually Transmitted Diseases (STD) Provider Education Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Mar 14, 2023 |
| Last Updated Date: | Mar 14, 2023 |
| Original Closing Date for Applications: | Apr 13, 2023 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Current Closing Date for Applications: | Apr 13, 2023 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Archive Date: | May 13, 2023 |
| Estimated Total Program Funding: | $550,000 |
| Award Ceiling: | $800,000 |
| Award Floor: | $250,000 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | This award will be a program supplement intended only for recipients previously awarded under Component A Core, B Core and C Core of CDC-RFA-PS20-2004, National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC). |
Additional Information
| Agency Name: | Centers for Disease Control – NCHHSTP |
| Description: | Mpox is a zoonotic infection caused by mpox virus, an orthopoxvirus with an unknown animal reservoir endemic in several Central and West African countries. Since mid-May 2022, the United States and many other countries without a history of mpox activity, have witnessed an increase in reported mpox cases. Although the primary mode of mpox transmission is close contact, meaning that anyone, regardless of gender identity or sexual orientation, can acquire mpox, most of those affected in the current global outbreaks are gay, bisexual, or other men who have sex with men (MSM). Close contact, sustained skin-to-skin contact including sexual contact with a person with mpox or contact with contaminated fomites (e.g., shared linens) are the most significant risk factors associated with human-to-human transmission of mpox virus and many have called to consider mpox a sexually transmitted infection (STI). Not only is the clinical presentation of mpox similar to some STIs, such as syphilis, herpes, lymphogranuloma venereum (LGV), or other etiologies of proctitis, but co-infections of mpox with STIs are common. Although the case-fatality rate for mpox in the current outbreak is low, infection can cause a significant degree of pain and morbidity, including hospitalization. There is no treatment specifically for mpox. However, because the mpox and smallpox viruses are closely related, drugs and vaccines developed to protect against smallpox may be used to prevent and treat mpox virus infections. Vaccination can be given as post-exposure prophylaxis (PEP) or as pre-exposure prophylaxis (PrEP).The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) are regional and national centers created in partnership with health departments and universities. NNPTC is dedicated to increasing the knowledge and skills of health professionals in the areas of sexual and reproductive health. The NNPTCs are well positioned to address mpox in the United States for several reasons including: 1) established expertise in infections transmitted through sexual contact 2) content expertise focused on MSM populations; 3) broad geographical reach of the network which covers the entire United States; 4) faculty with deep expertise in infectious diseases and public health.The purpose of this non-competitive supplemental Notice of Funding Opportunity (NOFO) is to fund components A, B, and C of the PS20-2004 NNPTC NOFO. This supplemental NOFO leverages the strengths of the NNPTCs to support public health efforts to address the mpox epidemic using a syndemic approach. PS20-2004 recipients will develop an implementation strategy to train and provide technical assistance to healthcare providers and clinical settings for the purposes of supporting the integration of mpox vaccination, diagnosis, and treatment activities into routine sexual health care using a syndemic approach. The training and technical support to be developed and delivered through this supplement will include aspects of epidemiology, transmission, clinical presentation, diagnostic testing, treatment, vaccination, and prevention. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Alexandra Coor
yfu3@cdc.gov Email:yfu3@cdc.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| updated the date | Mar 14, 2023 | |
| updated the due date | Mar 14, 2023 | |
| Mar 14, 2023 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-PS20-20040401SUPP23 |
| Funding Opportunity Title: | The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 93.978 — Sexually Transmitted Diseases (STD) Provider Education Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Mar 14, 2023 |
| Last Updated Date: | Mar 14, 2023 |
| Original Closing Date for Applications: | Apr 13, 2023 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Current Closing Date for Applications: | Apr 13, 2023 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Archive Date: | May 13, 2023 |
| Estimated Total Program Funding: | $550,000 |
| Award Ceiling: | $800,000 |
| Award Floor: | $250,000 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | This award will be a program supplement intended only for recipients previously awarded under Component A Core, B Core and C Core of CDC-RFA-PS20-2004, National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC). |
Additional Information
| Agency Name: | Centers for Disease Control – NCHHSTP |
| Description: | Mpox is a zoonotic infection caused by mpox virus, an orthopoxvirus with an unknown animal reservoir endemic in several Central and West African countries. Since mid-May 2022, the United States and many other countries without a history of mpox activity, have witnessed an increase in reported mpox cases. Although the primary mode of mpox transmission is close contact, meaning that anyone, regardless of gender identity or sexual orientation, can acquire mpox, most of those affected in the current global outbreaks are gay, bisexual, or other men who have sex with men (MSM). Close contact, sustained skin-to-skin contact including sexual contact with a person with mpox or contact with contaminated fomites (e.g., shared linens) are the most significant risk factors associated with human-to-human transmission of mpox virus and many have called to consider mpox a sexually transmitted infection (STI). Not only is the clinical presentation of mpox similar to some STIs, such as syphilis, herpes, lymphogranuloma venereum (LGV), or other etiologies of proctitis, but co-infections of mpox with STIs are common. Although the case-fatality rate for mpox in the current outbreak is low, infection can cause a significant degree of pain and morbidity, including hospitalization. There is no treatment specifically for mpox. However, because the mpox and smallpox viruses are closely related, drugs and vaccines developed to protect against smallpox may be used to prevent and treat mpox virus infections. Vaccination can be given as post-exposure prophylaxis (PEP) or as pre-exposure prophylaxis (PrEP).The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) are regional and national centers created in partnership with health departments and universities. NNPTC is dedicated to increasing the knowledge and skills of health professionals in the areas of sexual and reproductive health. The NNPTCs are well positioned to address mpox in the United States for several reasons including: 1) established expertise in infections transmitted through sexual contact 2) content expertise focused on MSM populations; 3) broad geographical reach of the network which covers the entire United States; 4) faculty with deep expertise in infectious diseases and public health.The purpose of this non-competitive supplemental Notice of Funding Opportunity (NOFO) is to fund components A, B, and C of the PS20-2004 NNPTC NOFO. This supplemental NOFO leverages the strengths of the NNPTCs to support public health efforts to address the mpox epidemic using a syndemic approach. PS20-2004 recipients will develop an implementation strategy to train and provide technical assistance to healthcare providers and clinical settings for the purposes of supporting the integration of mpox vaccination, diagnosis, and treatment activities into routine sexual health care using a syndemic approach. The training and technical support to be developed and delivered through this supplement will include aspects of epidemiology, transmission, clinical presentation, diagnostic testing, treatment, vaccination, and prevention. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Alexandra Coor
yfu3@cdc.gov Email:yfu3@cdc.gov |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-PS20-20040401SUPP23 |
| Funding Opportunity Title: | The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 93.978 — Sexually Transmitted Diseases (STD) Provider Education Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Mar 14, 2023 |
| Last Updated Date: | Mar 14, 2023 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 13, 2023 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Archive Date: | May 13, 2023 |
| Estimated Total Program Funding: | $550,000 |
| Award Ceiling: | $800,000 |
| Award Floor: | $250,000 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | This award will be a program supplement intended only for recipients previously awarded under Component A Core, B Core and C Core of CDC-RFA-PS20-2004, National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC). |
Additional Information
| Agency Name: | Centers for Disease Control – NCHHSTP |
| Description: | Mpox is a zoonotic infection caused by mpox virus, an orthopoxvirus with an unknown animal reservoir endemic in several Central and West African countries. Since mid-May 2022, the United States and many other countries without a history of mpox activity, have witnessed an increase in reported mpox cases. Although the primary mode of mpox transmission is close contact, meaning that anyone, regardless of gender identity or sexual orientation, can acquire mpox, most of those affected in the current global outbreaks are gay, bisexual, or other men who have sex with men (MSM). Close contact, sustained skin-to-skin contact including sexual contact with a person with mpox or contact with contaminated fomites (e.g., shared linens) are the most significant risk factors associated with human-to-human transmission of mpox virus and many have called to consider mpox a sexually transmitted infection (STI). Not only is the clinical presentation of mpox similar to some STIs, such as syphilis, herpes, lymphogranuloma venereum (LGV), or other etiologies of proctitis, but co-infections of mpox with STIs are common. Although the case-fatality rate for mpox in the current outbreak is low, infection can cause a significant degree of pain and morbidity, including hospitalization. There is no treatment specifically for mpox. However, because the mpox and smallpox viruses are closely related, drugs and vaccines developed to protect against smallpox may be used to prevent and treat mpox virus infections. Vaccination can be given as post-exposure prophylaxis (PEP) or as pre-exposure prophylaxis (PrEP).The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) are regional and national centers created in partnership with health departments and universities. NNPTC is dedicated to increasing the knowledge and skills of health professionals in the areas of sexual and reproductive health. The NNPTCs are well positioned to address mpox in the United States for several reasons including: 1) established expertise in infections transmitted through sexual contact 2) content expertise focused on MSM populations; 3) broad geographical reach of the network which covers the entire United States; 4) faculty with deep expertise in infectious diseases and public health.The purpose of this non-competitive supplemental Notice of Funding Opportunity (NOFO) is to fund components A, B, and C of the PS20-2004 NNPTC NOFO. This supplemental NOFO leverages the strengths of the NNPTCs to support public health efforts to address the mpox epidemic using a syndemic approach. PS20-2004 recipients will develop an implementation strategy to train and provide technical assistance to healthcare providers and clinical settings for the purposes of supporting the integration of mpox vaccination, diagnosis, and treatment activities into routine sexual health care using a syndemic approach. The training and technical support to be developed and delivered through this supplement will include aspects of epidemiology, transmission, clinical presentation, diagnostic testing, treatment, vaccination, and prevention. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Alexandra Coor
yfu3@cdc.gov Email:yfu3@cdc.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | CDC-RFA-PS20-20040401SUPP23 |
| Funding Opportunity Title: | The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 93.978 — Sexually Transmitted Diseases (STD) Provider Education Grants |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 14, 2023 |
| Last Updated Date: | Mar 14, 2023 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Apr 13, 2023 Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date. |
| Archive Date: | May 17, 2023 |
| Estimated Total Program Funding: | $550,000 |
| Award Ceiling: | $800,000 |
| Award Floor: | $250,000 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | This award will be a program supplement intended only for recipients previously awarded under Component A Core, B Core and C Core of CDC-RFA-PS20-2004, National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC). |
Additional Information
| Agency Name: | Centers for Disease Control – NCHHSTP |
| Description: | Mpox is a zoonotic infection caused by mpox virus, an orthopoxvirus with an unknown animal reservoir endemic in several Central and West African countries. Since mid-May 2022, the United States and many other countries without a history of mpox activity, have witnessed an increase in reported mpox cases. Although the primary mode of mpox transmission is close contact, meaning that anyone, regardless of gender identity or sexual orientation, can acquire mpox, most of those affected in the current global outbreaks are gay, bisexual, or other men who have sex with men (MSM). Close contact, sustained skin-to-skin contact including sexual contact with a person with mpox or contact with contaminated fomites (e.g., shared linens) are the most significant risk factors associated with human-to-human transmission of mpox virus and many have called to consider mpox a sexually transmitted infection (STI). Not only is the clinical presentation of mpox similar to some STIs, such as syphilis, herpes, lymphogranuloma venereum (LGV), or other etiologies of proctitis, but co-infections of mpox with STIs are common. Although the case-fatality rate for mpox in the current outbreak is low, infection can cause a significant degree of pain and morbidity, including hospitalization. There is no treatment specifically for mpox. However, because the mpox and smallpox viruses are closely related, drugs and vaccines developed to protect against smallpox may be used to prevent and treat mpox virus infections. Vaccination can be given as post-exposure prophylaxis (PEP) or as pre-exposure prophylaxis (PrEP).The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) are regional and national centers created in partnership with health departments and universities. NNPTC is dedicated to increasing the knowledge and skills of health professionals in the areas of sexual and reproductive health. The NNPTCs are well positioned to address mpox in the United States for several reasons including: 1) established expertise in infections transmitted through sexual contact 2) content expertise focused on MSM populations; 3) broad geographical reach of the network which covers the entire United States; 4) faculty with deep expertise in infectious diseases and public health.The purpose of this non-competitive supplemental Notice of Funding Opportunity (NOFO) is to fund components A, B, and C of the PS20-2004 NNPTC NOFO. This supplemental NOFO leverages the strengths of the NNPTCs to support public health efforts to address the mpox epidemic using a syndemic approach. PS20-2004 recipients will develop an implementation strategy to train and provide technical assistance to healthcare providers and clinical settings for the purposes of supporting the integration of mpox vaccination, diagnosis, and treatment activities into routine sexual health care using a syndemic approach. The training and technical support to be developed and delivered through this supplement will include aspects of epidemiology, transmission, clinical presentation, diagnostic testing, treatment, vaccination, and prevention. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Alexandra Coor
yfu3@cdc.gov Email:yfu3@cdc.gov |
Related Documents
Folder 346796 Full Announcement-Full Announcement -> Foa_Content_of_CDC-RFA-PS20-20040401SUPP23.pdf
Packages
| Agency Contact Information: | Alexandra Coor yfu3@cdc.gov Email: yfu3@cdc.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.978 | CDC-RFA-PS20-20040401SUPP23 | The National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers (NNPTC) Program Supplement | PKG00280496 | Mar 14, 2023 | Apr 13, 2023 | View |
Package 1
Mandatory forms
346796 SF424_4_0-4.0.pdf
346796 SF424A-1.0.pdf
346796 BudgetNarrativeAttachments_1_2-1.2.pdf
346796 ProjectNarrativeAttachments_1_2-1.2.pdf
346796 Project_Abstract_1_2-1.2.pdf
346796 Project_AbstractSummary_2_0-2.0.pdf
Optional forms
346796 OtherNarrativeAttachments_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
